August 25, 2018
A report from digital media firm GlobalData published in July 2018, suggests that only 54% of North Americans in the international drugs industry believe they are informed about the new European Union General Data Protection Regulation. This is contrary to the 84% figure for Europeans – and 67% for those in the Asia-Pacific region – working in the same sector.
The press release circulated by GlobalData together with the publication of the report said that those residing in North America are the least expected to say that they feel informed concerning the requirements of GDPR. The report asked workers from industry sectors who were questioned about modifications to their business practice because of GDPR, and their feelings in relation to the law. From the outcomes of the queries, GlobalData studied those given by workers from the drugs industry. The purpose of the study was to gain a better understanding of the factors which affect the healthcare sector and decide hurdles to GDPR compliance.
Thomas Moore, senior pharma expert at GlobalData said “These outcomes indicate that those in the United States drugs industry may be less prepared than in other areas when it comes to adopting the new business practices required to meet requirements set out by the GDPR. This opinion might be because of GDPR having possibly less of a direct impact on firms operating in North America than those in other international areas, which are often more reliant on EU business operations.”
“GDPR was a piece of law brought into effect by the EU on May 25, 2018, which wishes to provide EU residents with greater rights and control concerning the processing and distribution of their private data. Because of the complication of the rules, it is vital that companies stay highly informed should they desire to continue operating inside EU member states. GlobalData’s report aims to provide insight into how firms in the healthcare industry have reacted to GDPR internationally.”